LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Large Joints and Extremities/Personalized Shoulder Reconstruction Implant From Zimmer Biomet
Large Joints and Extremities

Personalized Shoulder Reconstruction Implant From Zimmer Biomet

November 22, 2016 2 min read Premium comments

Advertisement

Personalized Shoulder Reconstruction Implant From Zimmer Biomet
Comprehensive Vault Reconstruction System / Courtesy of Zimmer Biomet Holdings, Inc.
Secondary

Zimmer Biomet Holdings, Inc. has introduced a personalized shoulder implant called the Comprehensive Vault Reconstruction System (VRS) for patients with a severely deficient rotator cuff and extensive bone loss which precludes the use of a standard glenoid baseplate.

Until now, treatment options for extensive glenoid deficiencies were limited to bone grafting or hemi-arthroplasty, said David Dines, M.D. an orthopedic surgeon at the Hospital for Special Surgery in New York. Dr. Dines is also a professor of orthopedic surgery at Weill Cornell Medical College. Dines said the previous treatment options were “unreliable and had marginal success.”

CT Imaging and 3D Technique

The VRS uses CT imaging and advanced 3D reconstruction techniques to allow surgeons to personalize each patient’s implant.

In a November 17, 2016 company press announcement, Dines said the system “represents an important advance in shoulder reconstruction by streamlining and personalizing the implant procedure in hope of more predictable outcomes and results that extend beyond pain relief, to restoring function and improving overall quality of life.”

Stephen Brockmeier, M.D., performed the first VRS implantation on September 21, 2016, at the University of Virginia Hospital in Charlottesville, Virginia.

The VRS was cleared by the FDA May 2016, just eight months after Biomet Manufacturing Corp. filed a 510k premarket notification of intent to market the system with the agency.

Indications

Advertisement

According to the FDA substantial equivalent determination, the system is indicated for use “in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff. The patient must be anatomically and structurally suited to receive the implants and a functional deltoid muscle is necessary.

“The [system] is indicated for primary, fracture, or revision total shoulder replacement for the relief of pain and significant disability due to gross rotator cuff deficiency.

“Comprehensive Vault Reconstruction System glenoid baseplate components are intended for cementless application with the addition of screw fixation in patients with unusual anatomy and/or extensive bone loss which precludes the use of a standard glenoid baseplate component.

“Titanium glenospheres are intended for patients with Cobalt Alloy material sensitivity. The wear of these devices has not been tested but, based on pin on disk testing, the wear rate is inferior to that of cobalt alloy glenospheres. A Cobalt Alloy glenosphere is the recommended component for reverse shoulder arthroplasty patients without material sensitivity to cobalt alloy.

“Interlok finish humeral stems are intended for cemented use and the MacroBond coated humeral stems are intended for press-fit or cemented applications. Humeral components with porous coated surface coating are indicated for either cemented or uncemented biological fixation applications.”

Orsa Britton, vice president and general manager of Zimmer Biomet’s global extremities business, said this patient-specific implant, coupled with extensive pre-operative planning software, “will expand viable treatment options for patients with severe glenoid deformities.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy